BioInvent International

Research BioInvent International (BINV.ST) on Bullrun: market cap SEK 1.51B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerBINV.ST
ExchangeXSTO
CountrySweden
SectorHealthcare
IndustryBiotechnology
CurrencySEK
Market capSEK 1.51B
Financial periodQ1 2026
RevenueSEK 13.42M
Net income-SEK 119.22M
Free cash flow-SEK 133.45M

Valuation Snapshot

latest market cap is SEK 1.51B.

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-10-06	SEK 1.51B	n/a	n/a	0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 SEK.

About BioInvent International

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin's lymphoma, and solid tumors;

Related stock research

Sweden stocks Sweden Healthcare stocks A-Z stock index

Other Healthcare stocks

Abera Bioscience AB (ABERA.ST) Ascelia Pharma AB (publ) (ACE) AcouSort AB (ACOU) Active Biotech AB (ACTI) AlzeCure Pharma (ALZCUR) Alzinova (ALZ.ST) Annexin Pharmaceuticals (ANNX.ST) Alligator Bioscience AB (ATORX) BioArctic AB (publ) (BIOA-B) Biosergen AS (BIOSGN) Biovica International AB (publ) (BIOVIC-B) Camurus (CAMX.ST)

Frequently asked questions

What is BioInvent International's market cap?

BioInvent International's market capitalization is SEK 1.51B.

What does BioInvent International do?

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally.